Finally, we concluded that our in silico TGEM (conceptually defined by the permanent activation and inactivation of NFκB and HIF1-α, respectively) induced phenotypes against cancer cells in the tumor microenvironment. The gene discussed is HIF1A; the disease is neoplasm.